Answers are grounded in this paper and cite their sources.
ITx is a viable treatment in selected patients with FAP and extensive desmoid disease. The decision to refer for ITx can be challenging, particularly the timing and sequence of treatment (simultaneous versus sequential exenteration). Delays can result in additional disease burden, such as secondary liver disease or invasion of adjacent structures.
No takes yet. Share an insight, caveat, or question.
Canovai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: